William Blair Analysts Lower Earnings Estimates for Enovis

Enovis Co. (NYSE:ENOV) – Investment analysts at William Blair dropped their Q4 2024 earnings per share estimates for shares of Enovis in a research report issued to clients and investors on Wednesday, November 6th. William Blair analyst B. Vazquez now anticipates that the company will post earnings per share of $0.91 for the quarter, down from their previous forecast of $0.95. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. William Blair also issued estimates for Enovis’ Q4 2025 earnings at $0.96 EPS.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.11. The firm had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same quarter last year, the business posted $0.56 EPS.

A number of other equities analysts have also recently commented on the company. Evercore ISI reduced their price target on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. JPMorgan Chase & Co. reduced their price objective on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. JMP Securities began coverage on Enovis in a report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $67.00.

Enovis Price Performance

NYSE:ENOV opened at $47.36 on Monday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.27. The stock’s 50-day simple moving average is $42.24 and its 200 day simple moving average is $45.38. The company has a market cap of $2.65 billion, a P/E ratio of -21.63 and a beta of 1.91. Enovis has a 52-week low of $38.27 and a 52-week high of $65.03.

Institutional Investors Weigh In On Enovis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. River Road Asset Management LLC bought a new position in shares of Enovis during the 3rd quarter valued at approximately $51,341,000. American Century Companies Inc. grew its position in shares of Enovis by 78.6% during the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock valued at $68,337,000 after acquiring an additional 665,208 shares during the period. Magnetar Financial LLC grew its position in shares of Enovis by 66.7% during the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after acquiring an additional 442,051 shares during the period. Diamond Hill Capital Management Inc. grew its position in shares of Enovis by 14.5% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock valued at $125,929,000 after acquiring an additional 352,116 shares during the period. Finally, Royce & Associates LP grew its position in shares of Enovis by 16.8% during the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock valued at $103,479,000 after acquiring an additional 346,317 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.